

**30 August 2024**

## **Treatment of Dermatological Conditions**

**How many patients were treated in the last 4 months (April to July 2024) by the dermatology department with each of the following products:**

- **Abrocitinib** 7
- **Acitretin** 121
- **Alitretinoin** 19
- **Azathioprine** via GP
- **Baricitinib** <5
- **Ciclosporin** via GP
- **Dupilumab** 182
- **Lebrikizumab** 5
- **Methotrexate** via GP
- **Mycophenolate mofetil** via GP
- **Pimecrolimus** via GP
- **Phototherapy (UVB or PUVA)** for Atopic Dermatitis only. We are unable to access these figures
- **Tacrolimus ointment** via GP
- **Tralokinumab** <5
- **Upadacitinib** 36

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

**Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

- **Age 6-11** 14
- **Age 12-17** 23
- **Age 18 and above** 326